FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:2573-2576 June 23, 2005 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

In light of the success of the statin drugs, interest in preventive cardiology has shifted to new frontiers of pharmacologic intervention: defining optimal levels of low-density lipoprotein (LDL) cholesterol, inhibiting cholesterol absorption, addressing the inflammatory component of atherosclerosis, and increasing the levels of protective high-density lipoprotein (HDL) cholesterol. This last approach attracted attention last year when it was reported that a new drug, torcetrapib, could substantially increase levels of HDL cholesterol by inhibiting cholesteryl ester transfer protein.¹ The drug was heralded as a novel weapon against heart disease that could be an important clinical tool if its effect on lipids . . . [Full Text of this Article]

Source Information

Dr. Avorn is a professor of medicine at Harvard Medical School and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital — both in Boston.

Related Letters:

Torcetrapib and Atorvastatin
Shear C. L., Hirsch R. L., Green A. M., Avorn J.
Extract | Full Text | PDF  
N Engl J Med 2005; 353:1527-1529, Oct 6, 2005. Correspondence

This article has been cited by other articles:

• Whayne, T. F. Jr (2009). High-density Lipoprotein Cholesterol: Current Perspective for Clinicians. ANGIOLOGY 60: 644-649 [Abstract]  
• Mozaffarian, D., Wilson, P. W.F., Kannel, W. B. (2008). Beyond Established and Novel Risk Factors: Lifestyle Risk Factors for Cardiovascular Disease. Circulation 117: 3031-3038 [Full Text]  
• Noble, J. H. Jr, Sharav, V. H. (2008). Protecting People With Decisional Impairments and Legal Incapacity Against Biomedical Research Abuse. Journal of Disability Policy Studies 18: 230-244 [Abstract]  
• Brown, S. D., Daly, J. C., Kalish, L. A., McDaniel, S. A. (2006). Financial Disclosures of Scientific Papers Presented at the 2003 RSNA Annual Meeting: Association with Reporting of Non-Food and Drug Administration-approved Uses of Industry Products. Radiology 239: 849-855 [Abstract] [Full Text]  
• Kesselheim, A. S., Avorn, J. (2006). Biomedical Patents and the Public's Health: Is There a Role for Eminent Domain?. JAMA 295: 434-437 [Full Text]  
• Wild, S. H, Byrne, C. D (2005). Review: Treatment of lipids to reduce cardiovascular risk among people with the metabolic syndrome or type 2 diabetes. British Journal of Diabetes & Vascular Disease 5: 315-319 [Abstract]  
• Shear, C. L., Hirsch, R. L., Green, A. M., Avorn, J. (2005). Torcetrapib and atorvastatin.. NEJM 353: 1527-1529 [Full Text]